Background
Helicobacter pylori (H. pylori) is a common human pathogenic bacterium that is associated with gastric diseases. The current leading clinical therapy is combination antibiotics, but this treatment has safety issues, especially the induction of drug resistance. Therefore, developing a safe and effective vaccine against H. pylori is one of the best alternatives.
Objective
To develop Saccharomyces cerevisiae (S. cerevisiae)‐based oral vaccines and then demonstrate the feasibility of this platform for preventing H. pylori infection in the absence of a mucosal adjuvant.
Materials and Methods
Saccharomyces cerevisiae (S. cerevisiae)‐based oral vaccines, including EBY100/pYD1‐UreB and EBY100/pYD1‐VacA, were generated and analyzed by Western blot, Immunofluorescence analysis, flow cytometric assay, and indirect enzyme‐link immunosorbent assay (ELISA). Further, antibody responses induced by oral administration of EBY100/pYD1‐UreB, EBY100/pYD1‐VacA, or EBY100/pYD1‐UreB + EBY100/pYD1‐VacA were measured in a mouse model. Lastly, the vaccinated mice were infected with H. pylori SS1, and colonization in the stomach were evaluated.
Results
Saccharomyces cerevisiae‐based H. pylori oral vaccines were successfully constructed. Mice orally administered with EBY100/pYD1‐UreB, EBY100/pYD1‐VacA, or EBY100/pYD1‐UreB + EBY100/pYD1‐VacA exhibited a significant humoral immune response as well as a mucosal immune response. Importantly, S. cerevisiae‐based oral vaccines could effectively reduce bacterial loads with statistical significance after H. pylori infection.
Conclusions
Our study shows that S. cerevisiae‐based platforms can serve as an alternative approach for the future development of promising bacterial oral vaccine candidates.